Regenxbio (RGNX) Change in Receivables (2014 - 2025)
Regenxbio (RGNX) posted quarterly Change in Receivables of $561000.0 for Q4 2025, up 106.9% year-over-year from $271148.3 in Q4 2024, and down 91.11% quarter-over-quarter from $6.3 million in Q3 2025.
Regenxbio (RGNX) Change in Receivables (2014 - 2025) Analysis & Trends
Regenxbio's Change in Receivables history runs 12 years deep, the most recent figure standing at $561000.0 for Q4 2025.
- In Q4 2025, Change in Receivables rose 106.9% year-over-year to $561000.0; the TTM figure through Dec 2025 stood at $7.7 million (up 178.92% YoY), while the FY2025 annual figure was $7.7 million, up 178.92% from the prior year.
- Change in Receivables for Q4 2025 stood at $561000.0, down from $6.3 million in the prior quarter.
- The five-year high for Change in Receivables was $10.7 million in Q2 2022, with the low at -$22.0 million in Q4 2021.
- The 5-year median for Change in Receivables is -$505500.0 (2025), against an average of -$1.2 million.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables slumped 251.61% in 2022, then jumped 788.73% in 2025.
- Regenxbio's Change in Receivables stood at -$22.0 million in 2021, then surged by 77.99% to -$4.8 million in 2022, then surged by 30.45% to -$3.4 million in 2023, then sank by 141.41% to -$8.1 million in 2024, then surged by 106.9% to $561000.0 in 2025.
- Business Quant data shows RGNX's Change in Receivables at $561000.0 in Q4 2025, $6.3 million in Q3 2025, and $2.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 561,000.00 |
| Dec 31, 2025 | 561,000.00 |
| Sep 30, 2025 | 6.31 Mn |
| Sep 30, 2025 | 6.31 Mn |
| Jun 30, 2025 | 2.36 Mn |
| Jun 30, 2025 | 2.36 Mn |
| Mar 31, 2025 | -1.57 Mn |
| Mar 31, 2025 | -1.57 Mn |
| Dec 31, 2024 | -8.13 Mn |
| Dec 31, 2024 | -8.13 Mn |
| Sep 30, 2024 | 710,000.00 |
| Sep 30, 2024 | 710,000.00 |
| Jun 30, 2024 | 6.89 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | -9.18 Mn |
| Mar 31, 2024 | -9.18 Mn |
| Dec 31, 2023 | -3.37 Mn |
| Dec 31, 2023 | -3.37 Mn |
| Sep 30, 2023 | 6.54 Mn |
| Sep 30, 2023 | 6.54 Mn |